|1.||Livingston, Philip O: 14 articles (08/2012 - 02/2002)|
|2.||Ragupathi, Govind: 14 articles (08/2012 - 11/2003)|
|3.||Gin, David Y: 6 articles (08/2012 - 09/2006)|
|4.||Livingston, P O: 6 articles (08/2000 - 03/2000)|
|5.||Damani, Payal: 5 articles (08/2012 - 01/2008)|
|6.||Adams, Michelle M: 4 articles (08/2012 - 01/2008)|
|7.||Slovin, Susan F: 4 articles (12/2007 - 12/2003)|
|8.||Scher, Howard I: 4 articles (12/2007 - 12/2003)|
|9.||Diani, Meghan: 3 articles (12/2007 - 05/2005)|
|10.||Fernandez, Celina: 3 articles (12/2007 - 05/2005)|
10/20/2013 - "A total of 1,314 patients with a primary tumor > 1.50 mm in thickness (T3-4N0M0; American Joint Committee on Cancer stage II) were randomly assigned to GM2-KLH/QS-21 vaccination (n = 657) or observation (n = 657). "
07/15/2007 - "Pilot study of a heptavalent vaccine-keyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer."
06/01/2007 - "Immunization of Rhesus monkeys with a SialylTn-mAb17-1A conjugate vaccine co-formulated with QS-21 induces a temporary systemic cytokine release and NK cytotoxicity against tumor cells."
07/01/1999 - "Primary immunization with such a multiple antigenic peptide, along with QS-21 as adjuvant, elicits cytotoxic antibodies reactive with naturally occurring forms of TAC expressed on tumor cells, and vaccination of mice with peptide mimotopes reduced tumor growth and prolonged host survival in a murine tumor model."
07/15/1996 - "However, MUC1 peptides conjugated to KLH (MUCl-KLH), plus QS-21, induced high titer antibody against the immunizing peptides and against MUC1-expressing tumor cells. "
01/01/2009 - "However, a Phase II clinical trial of active immunization using full-length human Abeta1-42 peptide and a strong Th1-biased adjuvant, QS-21, ended prematurely in 2002 because of the onset of meningoencephalitis in approximately 6% of the AD patients enrolled in the study. "
03/20/2006 - "Immunization with Abeta42 formulated in the Th1-type adjuvant QS21 was beneficial for AD patients with significant titers of anti-Abeta antibodies, however, 6% of participants developed meningoencephalitis, likely due to anti-Abeta-specific autoimmune Th1 cells. "
11/01/2006 - "The meningoencephalitis observed in the first AD vaccination trial was likely related to excessive cell-mediated immunity caused by the immunogen, amyloid-beta (Abeta) 1-42, and the adjuvant, QS-21. "
02/01/2012 - "Unfortunately, the first active vaccine (AN1792, consisting of preaggregate Aβ and an immune adjuvant, QS-21) was abandoned because it caused meningoencephalitis in approximately 6% of treated patients. "
01/01/2008 - "A recent human clinical trial of an Alzheimer's disease (AD) vaccine using amyloid beta (Abeta) 1-42 plus QS-21 adjuvant produced some positive results, but was halted due to meningoencephalitis in some participants. "
09/13/2006 - "Melanoma, breast cancer, small cell lung cancer, prostate cancer, HIV-1, and malaria are among the numerous maladies targeted in more than 80 recent and ongoing vaccine therapy clinical trials involving QS-21 as a critical adjuvant component for immune response augmentation. "
10/01/1998 - "The malaria sporozoite vaccine candidate RTS,S, formulated with an oil-in-water emulsion plus the immunostimulants monophosphoryl lipid A and the saponin derivative QS21 (vaccine 3), recently showed superior efficacy over two other experimental formulations. "
03/29/2004 - "The immunogenicity of the synthetic malaria vaccine SPf66 has been recently improved by the application of new adjuvants as QS-21 saponin or poly-D,L-lactide-co-glycolide (PLGA) polymers. "
01/01/2000 - "The killer cell activity of mice vaccinated with F/rIL-12 (0.1 microg) plus 0.8 microg QS-21 was equivalent to that elicited after vaccination by experimental infection, or with an optimal dose of QS-21. "
03/01/1995 - "The capacity of F/QS-21 to facilitate local pulmonary immune responses was also examined and found to be similar to those induced by experimental infection. "
05/01/2006 - "While the QS21 showed mild toxicity, significant adjuvant effect on the anti-FML humoral response before and after infection, and decrease in liver relative weight, the deacylsaponins showed no toxicity, less haemolysis and antibody and DTH responses increased mainly after infection, still inducing a stronger Leishmania-specific in vitro splenocyte proliferation. "
03/01/1995 - "Formulation of the purified fusion protein of respiratory syncytial virus with the saponin QS-21 induces protective immune responses in Balb/c mice that are similar to those generated by experimental infection."
04/01/1995 - "A vaccine consisting of purified Escherichia coli-expressed recombinant full-length outer surface proteins A (OspA) and B (OspB) and the saponin adjuvant QS21 was evaluated for protection against Borrelia burgdorferi infection. "
|5.||Melanoma (Melanoma, Malignant)
10/20/2013 - "GM2-KLH/QS-21 vaccination does not improve outcome for patients with stage II melanoma."
02/17/2010 - "These novel, amide-modified, non-natural substances exhibit immunopotentiating effects in vivo that rival or exceed that of QS-21 in evaluations with the GD3-KLH melanoma conjugate vaccine. "
10/01/2001 - "in either of two adjuvants, Montanide ISA-51 or QS-21, to 22 patients with high-risk resected melanoma (stage IIB-IV). "
03/01/2001 - "GM2-KLH/QS-21 (GMK) is a chemically defined vaccine that is one of the best developed of a range of vaccine candidates for melanoma. "
08/01/2000 - "These results demonstrate that modest expansion of peptide-specific CD8(+) T cells can be generated in vivo by immunization with peptide plus QS-21 in at least a subset of patients with melanoma."
|2.||Immunologic Adjuvants (Immunologic Adjuvant)
|4.||keyhole-limpet hemocyanin (keyhole limpet hemocyanin)
|8.||monophosphoryl lipid A
|9.||Amyloid (Amyloid Fibrils)
|1.||Transplantation (Transplant Recipients)
|3.||Prostatectomy (Retropubic Prostatectomy)